[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-35802":3,"doc-seo-35802":29},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":4,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":21,"language":22,"language_code":23,"site_id":24,"html_lang":23,"table_of_contents":25,"faqs":26,"seo_title":13,"seo_description":14,"update_tm":27,"read_time":28},35802,7971461740909,"Levi","https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d",8,"Research & Report","Precision Cuproptosis Activation via HER2 Targeted Bimetallic MOF","Precision cuproptosis activation using a HER2-targeted bimetallic MOF is investigated as a research approach for improving antitumor effectiveness. The study focuses on aligning MOF-mediated copper-related cell death with HER2-directed recognition, aiming to enhance specificity toward HER2-expressing cancer cells. Experimental and analytical results support the concept that targeted delivery can potentiate cuproptosis while reducing off-target effects, offering a rationale for MOF-based precision cancer therapy.","","cbCainbwqO41GEOz","https://ap.wps.com/l/cbCainbwqO41GEOz","pdf",4818735,1,14,"English","en",105,"# Research Article Overview\n## Cuproptosis Activation Strategy\n## HER2 Targeting Mechanism\n## MOF-Based Precision Therapeutic Rationale","[{\"question\":\"How does the bimetallic MOF contribute to cuproptosis activation?\",\"answer\":\"The bimetallic MOF is positioned as the delivery/trigger platform that enables copper-related cell death pathways to be activated in a targeted manner.\"}]",1782594448,35,null]